Dr. Mamoun Alhamadsheh

Dr. Mamoun Alhamadsheh, the Co-founder at Eidos Therapeutics, is a Professor at the University of the Pacific. Most overdose deaths involve illicit synthetic opioids like fentanyl, the primary driver of the opioid epidemic today. The short duration of action (DOA) of opioid antagonists, naloxone and nalmefene, poses a significant challenge to their efficacy against fentanyl overdose, especially in mass casualty cases. Dr. Alhamadsheh and his team are developing a fundamentally novel drug delivery approach for extending the duration of action and efficacy of currently FDA-approved opioid overdose antidotes.